Innovation

Promising drug candidate protects against radiation exposure from nuclear fallout

A drug candidate called DBIBB that increases the survival of mice suffering from radiation syndrome, even when treatment started three days after radiation exposure, has been identified by scientists. The findings suggest that DBIBB shows promise for becoming the first drug capable of treating acute radiation syndrome caused by the high levels of radiation released by nuclear explosions.